OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
June 06, 2023 09:30 ET
|
OKYO Pharma LTD
Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain componentTop-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June 06,...
Dry Eye Syndrome Market Size to Surpass USD 11.26 Billion in 2030, exhibiting a CAGR of 7.0%
May 24, 2023 09:27 ET
|
Fortune Business Insights
Pune, India, May 24, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, global Dry Eye Syndrome Market size was valued at USD 6.61 billion in 2022 and is projected to grow from USD...
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
May 11, 2023 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development
May 03, 2023 03:00 ET
|
Vaccentis AG
Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
May 03, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
May 02, 2023 02:00 ET
|
OKYO Pharma LTD
Trial designed with pre-specified primary efficacy endpoints discussed previously with FDAIf successful, this phase 2 trial may serve as one of the two required phase 3 studies necessary to support...
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
April 25, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Global Dry Eye Syndrome Treatment Market Report 2023: Growing Investment in the Healthcare Industry Fuel the Sector
April 17, 2023 11:28 ET
|
Research and Markets
Dublin, April 17, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Syndrome Treatment - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Indication, By Product Type, By...
Keratoconjunctivitis Sicca (Dry Eye) Clinical Trial Analysis Report 2023: Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries
April 14, 2023 08:53 ET
|
Research and Markets
Dublin, April 14, 2023 (GLOBE NEWSWIRE) -- The "Keratoconjunctivitis Sicca (Dry Eye) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top...
Notice of Intention to Delist From The London Stock Exchange
April 04, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is...